Explore opportunities with Novartis below.
Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance ...
Coartem Baby was developed by Novartis with the scientific and financial support of MMV, and as part of the PAMAfrica ...
studies were published in Nature Medicine. Following the CHMP’s recommendation for approval, the European Commission (EC) is expected to issue a final decision within approximately two months. About ...
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed ...
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early ...
Max leads AI innovation in pharmaceutical development at Novartis. His story reflects how cutting-edge technology is combined with human expertise for meaningful impact. “I didn’t set out to work in ...
. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result ...
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut ...
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1 Distinction expedites development and review of treatments for serious ...
East Hanover, January 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ianalumab for Sjögren’s disease, the second ...
Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricing Additional Novartis medicines will be made available through direct-to-patient platforms in 2026 Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results